Jennifer M. Umhoefer
Research Subjects
Jennifer M. Umhoefer has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Marson
University of California, San Francisco 1 Department of Medicine San Francisco, California
2 shared publications Maya M. Arce
Gladstone-UCSF Institute of Genomic Immunology, San Francisco, USA
2 shared publicationsRama Dajani
Gladstone-UCSF Institute of Genomic Immunology, San Francisco, USA
2 shared publications- Andrew S. Khalil
John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA
1 shared publication - Anika Wadhera
Gladstone-UCSF Institute of Genomic Immunology, San Francisco, USA
1 shared publication Ansuman T. Satpathy
1 shared publication
Latest Publications
- Open Access
- 11 December 2024
- Published by Springer Nature in Nature
- Vol. 637 (8047) , 930-939
Central control of dynamic gene circuits governs T cell rest and activation
The ability of cells to maintain distinct identities and respond to transient environmental signals requires tightly controlled regulation of gene networks1–3. These dynamic regulatory circuits that respond to extracellular cues in primary human cells remain poorly defined. The need for context-dependent regulation is prominent in T cells, where distinct lineages must respond to diverse signals to mount effective immune responses and maintain homeostasis4–8. Here we performed CRISPR screens in multiple primary human CD4+ T cell contexts to identify regulators that control expression of IL-2Rα, a canonical marker of T cell activation transiently expressed by pro-inflammatory effector T cells and constitutively expressed by anti-inflammatory regulatory T cells where it is required for fitness9–11. Approximately 90% of identified regulators of IL-2Rα had effects that varied across cell types and/or stimulation states, including a subset that even had opposite effects across conditions. Using single-cell transcriptomics after pooled perturbation of context-specific screen hits, we characterized specific factors as regulators of overall rest or activation and constructed state-specific regulatory networks. MED12 — a component of the Mediator complex — serves as a dynamic orchestrator of key regulators, controlling expression of distinct sets of regulators in different T cell contexts. Immunoprecipitation–mass spectrometry revealed that MED12 interacts with the histone methylating COMPASS complex. MED12 was required for histone methylation and expression of genes encoding key context-specific regulators, including the rest maintenance factor KLF2 and the versatile regulator MYC. CRISPR ablation of MED12 blunted the cell-state transitions between rest and activation and protected from activation-induced cell death. Overall, this work leverages CRISPR screens performed across conditions to define dynamic gene circuits required to establish resting and activated T cell states.
- 11 December 2024
- Published by Springer Nature in Nature
- Vol. 637 (8047) , 930-939
Open AccessCentral control of dynamic gene circuits governs T cell rest and activation
The ability of cells to maintain distinct identities and respond to transient environmental signals requires tightly controlled regulation of gene networks1–3. These dynamic regulatory circuits that respond to extracellular cues in primary human cells remain poorly defined. The need for context-dependent regulation is prominent in T cells, where distinct lineages must respond to diverse signals to mount effective immune responses and maintain homeostasis4–8. Here we performed CRISPR screens in multiple primary human CD4+ T cell contexts to identify regulators that control expression of IL-2Rα, a canonical marker of T cell activation transiently expressed by pro-inflammatory effector T cells and constitutively expressed by anti-inflammatory regulatory T cells where it is required for fitness9–11. Approximately 90% of identified regulators of IL-2Rα had effects that varied across cell types and/or stimulation states, including a subset that even had opposite effects across conditions. Using single-cell transcriptomics after pooled perturbation of context-specific screen hits, we characterized specific factors as regulators of overall rest or activation and constructed state-specific regulatory networks. MED12 — a component of the Mediator complex — serves as a dynamic orchestrator of key regulators, controlling expression of distinct sets of regulators in different T cell contexts. Immunoprecipitation–mass spectrometry revealed that MED12 interacts with the histone methylating COMPASS complex. MED12 was required for histone methylation and expression of genes encoding key context-specific regulators, including the rest maintenance factor KLF2 and the versatile regulator MYC. CRISPR ablation of MED12 blunted the cell-state transitions between rest and activation and protected from activation-induced cell death. Overall, this work leverages CRISPR screens performed across conditions to define dynamic gene circuits required to establish resting and activated T cell states.
- Open Access
Cis-Regulatory Element and Transcription Factor Circuitry Required for Cell-Type Specific Expression of FOXP3
SUMMARY: FOXP3 is a lineage-defining transcription factor (TF) for immune-suppressive regulatory T cells (Tregs). While mice exclusively express FOXP3 in Tregs, humans also transiently express FOXP3 in stimulated conventional CD4+ T cells (Tconvs). Mechanisms governing these distinct expression patterns remain unknown. Here, we performed CRISPR screens tiling the FOXP3 locus and targeting TFs in human Tregs and Tconvs to discover cis-regulatory elements (CREs) and trans-regulators of FOXP3. Tconv FOXP3 expression depended on a subset of Treg CREs and Tconv-selective positive (TcNS+) and negative (TcNS-) CREs. The CREs are occupied and regulated by TFs we identified as critical regulators of FOXP3. Finally, mutagenesis of murine TcNS- revealed that it is critical for restriction of FOXP3 expression to Tregs. We discover CRE and TF circuitry controlling FOXP3 expression and reveal evolution of mechanisms regulating a gene indispensable to immune homeostasis. Highlights: Comprehensive CRISPR maps of CREs and TFs controlling FOXP3 in human Tregs and Tconvs Key TFs that control FOXP3 directly occupy and regulate CREs forming TF-CRE circuits A previously unknown negative CRE stringently restricts FOXP3 to Tregs in mice
Open AccessCis-Regulatory Element and Transcription Factor Circuitry Required for Cell-Type Specific Expression of FOXP3
SUMMARY: FOXP3 is a lineage-defining transcription factor (TF) for immune-suppressive regulatory T cells (Tregs). While mice exclusively express FOXP3 in Tregs, humans also transiently express FOXP3 in stimulated conventional CD4+ T cells (Tconvs). Mechanisms governing these distinct expression patterns remain unknown. Here, we performed CRISPR screens tiling the FOXP3 locus and targeting TFs in human Tregs and Tconvs to discover cis-regulatory elements (CREs) and trans-regulators of FOXP3. Tconv FOXP3 expression depended on a subset of Treg CREs and Tconv-selective positive (TcNS+) and negative (TcNS-) CREs. The CREs are occupied and regulated by TFs we identified as critical regulators of FOXP3. Finally, mutagenesis of murine TcNS- revealed that it is critical for restriction of FOXP3 expression to Tregs. We discover CRE and TF circuitry controlling FOXP3 expression and reveal evolution of mechanisms regulating a gene indispensable to immune homeostasis. Highlights: Comprehensive CRISPR maps of CREs and TFs controlling FOXP3 in human Tregs and Tconvs Key TFs that control FOXP3 directly occupy and regulate CREs forming TF-CRE circuits A previously unknown negative CRE stringently restricts FOXP3 to Tregs in mice
- Open Access
- 3 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (27) , eaba2422
Single-dose mRNA therapy via biomaterial-mediated sequestration of overexpressed proteins
Nanostructured mineral coatings delivering chemically modified or unmodified therapeutic mRNA improve diabetic wound healing.
- 3 July 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (27) , eaba2422
Open AccessSingle-dose mRNA therapy via biomaterial-mediated sequestration of overexpressed proteins
Nanostructured mineral coatings delivering chemically modified or unmodified therapeutic mRNA improve diabetic wound healing.